EGFR and breast cancer: Moreover, M2-like TAM activated BC cells via the EGFR/PI3K/AKT signaling pathway and upregulated sodium/glucose cotransporter 1 (SGLT1), leading to tamoxifen resistance and tumor growth (Niu et al., 2021).